Zai Lab Ltd. Q4 FY2024 earnings call

• 2024 was a pivotal year with strong commercial performance, including VYVGART's excellent first full year of launch generating $93.6 million in 2024 sales. - Launched several new products such as VYVGART Hytrulo for gMG and CIDP, AUGTYRO for ROS1 non-small cell lung cancer, and XACDURO for baumannii infections. - Reported positive data readouts for KarXT for schizophrenia, Tumor Treating Fields for pancreatic cancer, and TIVDAK for cervical cancer. - Advanced global pipeline with ZL-1310 showing promising preliminary results in small cell lung cancer, moving from Phase 1 initiation in January 2024 to potential pivotal trial. - Optimized cost structure, with loss from operations in the fourth quarter and full year improving year-over-year by 45% and 23% respectively.

In 2024, Zai Lab's total revenue grew 50% year-on-year, with a remarkable 66% growth in the fourth quarter. VYVGART had an excellent first full year of launch, generating $93.6 million in sales in 2024. Fourth quarter total revenue was $109.1 million, and full year net product revenue was $397.6 million, reflecting a robust 49% year-on-year growth. Key products like VYVGART, ZEJULA, and NUZYRA contributed to this growth. VYVGART's sales in 2024 were $93.6 million, and the fourth quarter saw strong contributions from these products, with VYVGART specifically driving significant growth in the immunology segment.

• Anticipates 2025 total revenues to be in the range of $560 million to $590 million. - On track to reach profitability in the fourth quarter of 2025. - Has a robust cash position of $879.7 million to support next phase of growth.

• Risks associated with SEC filings, including uncertainties due to various factors that may cause actual results to differ materially from expectations, such as regulatory approval processes and competitive landscape. - Uncertainties in the timely advancement of pipeline programs and potential delays in clinical trial results and regulatory submissions.

Q: On 2025 revenue guidance and products beyond VYVGART, A: Josh Smiley mentioned that ZEJULA and NUZYRA are particular growth drivers, VYVGART is expected to grow faster than the overall rate implied in the revenue range, and there will be contributions from the newly launched AUGTYRO and XACDURO.

Q: On VYVGART growth trajectory and ZEJULA, A: Josh Smiley stated that VYVGART has momentum with compounding growth from new patients and those in the maintenance phase, and midyear update to gMG guidelines in China will be a tailwind, while ZEJULA continues to be a leading PARP inhibitor for ovarian cancer in hospital sales in China.

Q: On DLL3 ADC ZL-1310's pivotal study and regulatory strategy, A: Rafael Amado discussed plans to start the pivotal study this year, potential for accelerated approval, and ongoing regulatory discussions with FDA, noting the competitive dynamics and speed of advancement.

Q: On CIDP and VYVGART subcutaneous formula, A: Josh Smiley mentioned that VYVGART Hytrulo for CIDP has limited impact in 2025 due to no NRDL listing, with focus on gMG in the immunology segment.

Q: On pipeline catalysts and key events, A: Samantha Du highlighted upcoming data updates for ZL-1310, bemarituzumab data readouts, multiple regulatory submissions in China in 2025, and the goal to achieve profitability in Q4 2025